Literature DB >> 16127597

Probiotic amelioration of azotemia in 5/6th nephrectomized Sprague-Dawley rats.

Natarajan Ranganathan1, Beena Patel, Pari Ranganathan, Joseph Marczely, Rahul Dheer, Tushar Chordia, Stephen R Dunn, Eli A Friedman.   

Abstract

The present study was to test the hypothesis that, selected bacteria instilled into the gastrointestinal tract could help in converting nitrogenous wastes accumulated due to renal insufficiency into non-toxic compounds; thereby, ameliorating the biochemical imbalance. Herein we describe a prospective, blinded, placebo controlled pilot-study, using 5/6th nephrectomized Sprague Dawley rat, as a chronic renal failure model. The study group consisted of 36 nephrectomized and 7 non-nephrectomized (control) rats. After two-week nephrectomy stabilization, cohorts of six nephrectomized rats were fed casein-based diet plus one of the following regimens: (A) Control, (B) Placebo (casein-based diet without probiotics), (C) Bacillus pasteurii, (D) Sporolac(R), (E) Kibow cocktail, (F) CHR Hansen Cocktail, and (G) ECONORM. Subsequently, blood (retro-orbital) and urine (collected for measurements of blood urea-nitrogen and creatinine respectively), body weight and bacterial counts (feces) were obtained at regular intervals. The study end-points were to determine if any of the probiotic dietary supplements facilitated, (1) decreased blood concentrations of uremic toxins, (2) altered renal function, and (3) prolonged survival. After 16 weeks of treatment, regimens C and D significantly prolonged the life span of uremic rats, in addition to showing a reduction in blood urea-nitrogen levels, concluding that supplementation of probiotic formulation to uremic rats slows the progression of azotemia, which may correlate with prolonged life span of uremic rats. Derivative trials of probiotic treatment of larger animals and humans will further assess the potential role of probiotic formulations in delaying the onset and clinical severity of clinical illness at different stages of renal failure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16127597      PMCID: PMC5936581          DOI: 10.1100/tsw.2005.86

Source DB:  PubMed          Journal:  ScientificWorldJournal        ISSN: 1537-744X


  20 in total

Review 1.  Probiotics and chronic kidney disease.

Authors:  Laetitia Koppe; Denise Mafra; Denis Fouque
Journal:  Kidney Int       Date:  2015-09-16       Impact factor: 10.612

Review 2.  Resistant starch for modulation of gut microbiota: Promising adjuvant therapy for chronic kidney disease patients?

Authors:  Cristiane Moraes; Natália A Borges; Denise Mafra
Journal:  Eur J Nutr       Date:  2016-01-30       Impact factor: 5.614

Review 3.  Clinical and experimental use of probiotic formulations for management of end-stage renal disease: an update.

Authors:  Alessandro Di Cerbo; Federica Pezzuto; Lucia Palmieri; Valentina Rottigni; Tommaso Iannitti; Beniamino Palmieri
Journal:  Int Urol Nephrol       Date:  2013-04-13       Impact factor: 2.370

4.  Effects of Probiotics on Inflammation and Uremic Toxins Among Patients on Dialysis: A Systematic Review and Meta-Analysis.

Authors:  Charat Thongprayoon; Wisit Kaewput; Spencer T Hatch; Tarun Bathini; Konika Sharma; Karn Wijarnpreecha; Patompong Ungprasert; Matthew D'Costa; Michael A Mao; Wisit Cheungpasitporn
Journal:  Dig Dis Sci       Date:  2018-08-11       Impact factor: 3.199

Review 5.  Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies.

Authors:  Wei Pan; Yongbo Kang
Journal:  Int Urol Nephrol       Date:  2017-08-28       Impact factor: 2.370

6.  Effects of probiotic VSL#3 on glomerular filtration rate in dogs affected by chronic kidney disease: A pilot study.

Authors:  Ilaria Lippi; Francesca Perondi; Gianila Ceccherini; Veronica Marchetti; Grazia Guidi
Journal:  Can Vet J       Date:  2017-12       Impact factor: 1.008

Review 7.  Gut microbiota and chronic kidney disease: evidences and mechanisms that mediate a new communication in the gastrointestinal-renal axis.

Authors:  Natalia Lucía Rukavina Mikusic; Nicolás Martín Kouyoumdzian; Marcelo Roberto Choi
Journal:  Pflugers Arch       Date:  2020-02-17       Impact factor: 3.657

Review 8.  The gut microbiome, kidney disease, and targeted interventions.

Authors:  Ali Ramezani; Dominic S Raj
Journal:  J Am Soc Nephrol       Date:  2013-11-14       Impact factor: 10.121

9.  Therapeutic potential of different commercially available synbiotic on acetaminophen-induced uremic rats.

Authors:  Arpita Mandal; Arpita Patra; Shreya Mandal; Suchismita Roy; Shreya Das Mahapatra; Tapasi Das Mahapatra; Tanmay Paul; Koushik Das; Keshab Chandra Mondal; Dilip Kumar Nandi
Journal:  Clin Exp Nephrol       Date:  2014-04-17       Impact factor: 2.801

Review 10.  Gut microbiome in chronic kidney disease: challenges and opportunities.

Authors:  Anitha Nallu; Shailendra Sharma; Ali Ramezani; Jagadeesan Muralidharan; Dominic Raj
Journal:  Transl Res       Date:  2016-04-30       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.